Treating agitation with dexmedetomidine in the ICU

Dimensions of Critical Care Nursing

Volumn 28, Issue 3, 2009, Pages 102-109

  Boyer, Jeanne ^a,b,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NONE   (United States)

Author keywords

Agitation; Anxiety; Dexmedetomidine; Sedation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE; HYPNOTIC SEDATIVE AGENT;

ACUTE DISEASE; CONSCIOUS SEDATION; DRUG EFFECT; DRUG MONITORING; HISTOLOGY; HUMAN; INTENSIVE CARE; LOCUS CERULEUS; METABOLIC CLEARANCE RATE; METHODOLOGY; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PHYSIOLOGY; PRACTICE GUIDELINE; RESTLESSNESS; REVIEW; TISSUE DISTRIBUTION;

ACUTE DISEASE; ADRENERGIC ALPHA-AGONISTS; CONSCIOUS SEDATION; DEXMEDETOMIDINE; DRUG MONITORING; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; LOCUS COERULEUS; METABOLIC CLEARANCE RATE; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; PSYCHOMOTOR AGITATION; RECEPTORS, ADRENERGIC, ALPHA-2; TISSUE DISTRIBUTION;

EID: 67651056402     PISSN: 07304625     EISSN: 15388646     Source Type: Journal    
DOI: 10.1097/DCC.0b013e31819aef3d     Document Type: Article

References (37)

1. Pun B, Dunn J. The sedation of critically ill adults: part 1: assessment. Am J Nurs. 2007;107(7):40-48.
2. DeJong MJ, Burns SM, Campbell ML, et al. Development of the American Association of Critical-Care Nurses' Sedation Assessment Scale for critically ill patients. Am J Crit Care. 2005;14(6):531-544.
3. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119-141.
4. Ostermann M, Keenan S, Seiferling R, Sibbald WJ. Sedation in the intensive care unit: A systematic review. JAMA. 2000; 283(11):1451-1459.
5. Merriam-Webster Medical Dictionary. 10th ed. Springfield, MA: Merriam-Webster Inc; 2005.
6. Caumo W, Schmidt AP, Schneider CN, et al. Risk factors for postoperative anxiety in adults. Anesthesia. 2001;56:720-728.
7. Porth C. Pathophysiology, concepts of altered health states. 7th ed. Baltimore, MD: Lippincott; 2005.
8. Ely W, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291:1753-1762.
9. Pun B, Dunn J. The sedation of critically ill adults: part 2: management. Am J Nurs. 2007;107(8):40-49.
10. Ramsay M, Savage TM, Simpson BRJ. Controlled Sedation with Alphaxalone-Alphadolone. Br Med J. 1974;2(920):656-659.
11. Dunn P. Clinical Anesthesia Procedures of the Massachusetts General Hospital. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
12. Vasile R, Rasulo F, Condiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29(9):1417-1425.
13. Hassan E, Fontaine K, Nearman H. Therapeutic considerations in the management of agitated or delirious critically ill patients. Pharmacotherapy. 1998;18(1):113-129.
14. Nasraway S, Jacobi J, Murray MJ, Lumb PD. Sedation, analgesia, and neuromuscular blockade of the critically ill adult: revised clinical practice guidelines for 2002. Crit Care Med. 2002;30(1):117-118.
15. Maze M. Sedation in the intensive care unit. Int Congr Symp Ser - Redefining Sedation. 1998;221:3-10.
16. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin. 2001;17(4):881-897.
17. Llorente D, Golden A, Silverman MA. Defining patterns of benzodiazepine use in older adults. J Geriatr Psychiatry Neurol. 2000;13:150-160.
18. Frangoulidou E, Kuhlen R, Marenghi C. Sedative agents and respiratory depression: a unique profile of dexmedetomidine. Int Congr Symp Ser - Redefining Sedation. 1998;221:41-50.
19. Barke K, Hough L. Opiates, mast cells and histamine release. Life Sci. 1993;53(18):1391-1399.
20. Griffioen K, Venkatesan P, Huang ZG, et al. Fentanyl inhibits GABAergic neurotransmission to cardiac vagal neurons in the nucleus ambiguus. Brain Res. 2004;1007(1-2):109.
21. Merriman H. The techniques used to sedate ventilated patients. Intensive Care Med. 1981;7:217-224.
22. Shapiro B, Warren J, Egol A, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Crit Care Med. 1995;23:1596-1600.
23. Pandharipande P, Pun B, Herr D, et al. The MENDS study: a double blind randomized controlled trial comparing efficacy of long-term sedation and duration of delirium and coma with dexmedetomidine versus lorazepam in mechanically ventilated medical and surgical patients. JAMA. 2007;298(22):2644-2653.
24. Gertler R, Brown C, Mitchell D, Silvius E. Dexmedetomidine: a novel sedative-analgesic agent. BUMC Proc. 2001;14:13-21.
25. Coursin D, Maccioli G. Dexmedetomidine. Curr Opin Crit Care. 2001;7:221-226.
26. Morrison P, Etropolski M, Bachand R. Dexmedetomidine and sedation: a dose-ranging study. Drugs. 2000;59(2):263-268.
27. Grounds R, Martin E, and Dexmedetomidine Study Group. A novel approach to managing post surgical patients in intensive care; use of a highly specific alpha2-adrenoceptor agonist. Intensive Care Med. 2003;29(2):201-207.
28. Maze M. Clinical uses of a2 agonists. In: Barash PG, ed. The American Society of Anesthesiologists, vol 20. Philadelphia, PA: Lippincott JB; 1992:133-142.
29. Levy J. Dexmedetomidine: Clinical Applications and Considerations. Atlanta, GA: Emory Healthcare; 2000. www. dexmedetomidine.com. Accessed October 2007.
30. Nelson L, Lu J, Guo T, Saper C, Franks C, Maze M. The alpha2-adrenoceptor agonist Dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98(2):428-436.
31. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93:1345-1349.
32. http://sofiatopia.org/equiaeon/ibrain8.jpg. Accessed September 2007.
33. Abramov D, Nogid B, Nogid A. The role of dexmedetomidine (Precedex) in the sedation of critically ill patients. Pharm Ther. 2005;30(3):158-161.
34. Hall J, Uhrich T, Barney J, Arain S, Ebert T. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699-705.
35. Precedex [product label]. Abbott Park, IL: Abbott Laboratories Inc.; 2004.
36. Bhana N, Goa K, McClellan K. Dexmedetomidine. Drugs. 2000;59(2):263-268.
37. Venn R, Hell J, Grounds M. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4:302-308.